Citigroup Maintains Buy on Amylyx Pharma, Raises Price Target to $50

Citigroup analyst Neena Bitritto-Garg maintains Amylyx Pharma (NASDAQ:AMLX) with a Buy and raises the price target from $48 to $50.

Citigroup analyst Neena Bitritto-Garg maintains Amylyx Pharma (NASDAQ:AMLX) with a Buy and raises the price target from $48 to $50.

Total
0
Shares
Related Posts